This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
F-18 fluoroestradiol (FES)-PET scans can predict whether or not endocrine therapy may be effective in women with estrogen receptor (ER)-positive breast cancer, according to a study published March 13 in the Journal of NuclearMedicine. Image courtesy of the Journal of NuclearMedicine. A visual abstract of the analysis.
The finding is from a preliminary analysis of 23 patients enrolled in an ongoing clinical trial, noted Giorgio Brembilla, MD, PhD, of the IRCCS San Raffaele Scientific Institute in Milan, Italy. The trial will eventually enroll 167 undiagnosed patients with suspected disease who have been referred for biopsies, Brembilla noted.
Preliminary studies suggest the tracer may also be effective in patients with earlier, more treatable stages of the disease, yet most of these studies have been retrospective and subject to a large risk of bias, the authors noted. The full study is available here.
The recommendations could improve patient care, as current clinical tools are often insufficient in complicated cases, noted lead author of the guidance Jamieson Bourque, MD, of the University of Virginia Health System in Charlottesville. The recommendations emphasize the complementary nature of these advanced nuclearmedicine exams.
The study was published February 13 in the Journal of NuclearMedicine. Image courtesy of the Journal of NuclearMedicine. Thus, with further development in larger trials, Ga-68 FZ-NR-1 could play a significant clinical role, they suggested. The full study is available here.
Patients with less tau pathology on PET scans may respond better to treatment with the new Alzheimer’s disease drug donanemab, according to an October 25 news report in the journal Practical Neurology. Research suggests that the accumulation of these proteins is a continuous process that starts decades before the onset of symptoms.
PET/CT imaging using gallium-68 (Ga-68) Fibroblast activation protein inhibitor (FAPI) radiotracer over F-18 FDG appears promising in women with invasive lobular carcinoma (ILC), according to a study published March 14 in the Journal of NuclearMedicine. Image courtesy of the Journal of NuclearMedicine.
PET brain scans show persistent brain inflammation in patients with multiple sclerosis (MS), despite being treated with high-efficacy disease-modifying therapies, according to a recent study by researchers in Boston. Image courtesy of ClinicalNuclearMedicine. The full article is available here.
Middlebrooks, MD, Mayo Clinic, Jacksonville, FL Erik H. Middlebrooks, MD, of the Mayo Clinic in Jacksonville, FL. Importantly, we are gaining deeper insights into disease processes themselves, which enhances our ability to diagnose and potentially treat conditions that were previously beyond our reach." Middlebrooks, MD.
Most Influential Radiology Researcher Erik Middlebrooks, MD, Mayo Clinic, Jacksonville, FL Erik Middlebrooks, MD. One of this year's nominations for Most Influential Radiology Researcher is Erik Middlebrooks, MD, of the Mayo Clinic in Jacksonville, FL. But we're still just scratching the surface."
Eliot Siegel, MD; Stanislav Spiridonov, MD; Nathan Gee, MD; and Anthony Chang, PhD, are among a niche gathering of early adopters, entrepreneurial physicians, medical physicists, and investors with a sweet spot for nuclearmedicine, diagnostic radiology, and radiation oncology.
Fibroblast activation protein inhibitor (FAPI)-PET/CT appears superior to standard FDG-PET/CT for detecting gastrointestinal cancer, with higher radiotracer uptake seen in most tumors, according to a study published October 26 in the Journal of NuclearMedicine. Image courtesy of the Journal of NuclearMedicine.
PET/CT imaging with F-18 sodium fluoride (NaF) is emerging as a sensitive tool for detecting early atherosclerosis, according to a presentation at the recent Society of NuclearMedicine and Molecular Imaging (SNMMI) annual meeting.
New imaging and treatment strategies are emerging to prolong the lives of men with metastatic castration-resistant prostate cancer (mCRPC), according to a presentation at the recent Society of NuclearMedicine and Molecular Imaging (SNMMI) annual meeting. Now there’s Pluvicto, she said.
FAPI-PET imaging could emerge as a new tool for assessing patients with single pulmonary tumors, especially in those with negative results on other scans, according to a study published April 11 in the Journal of NuclearMedicine. FAPI-PET either confirmed or ruled out the disease in all cases, the group found.
They're also mindful of the multiple dedicated teams required to build a theranostics clinic properly. Hope, vice chair of clinical operations and strategy in the UCSF department of radiology, established the radioligand therapy group at the university. Theranostics is becoming a treatment option for a larger volume of cancer patients.
In a comparative imaging trial, fibroblast activation protein inhibitor (FAPI)-PET/CT outperformed FDG-PET/CT in detecting primary tumors in patients with head and neck cancer, according to a study published January 25 in the Journal of NuclearMedicine. Image courtesy of the Journal of NuclearMedicine.
Up to 80% of women with the disease who respond to first-line chemotherapy relapse within 18 months, the authors explained. To explore the additional value of the technique, the researchers thus analyzed the relationship between MTV and TLG on pretreatment F-18 FDG-PET/CT and clinical outcomes. DEED, Attribution 4.0 vs. 30 months).
A new PET radiotracer has the potential for visualizing responses in liver cancer patients undergoing immunotherapy, according to a study published December 12 in the Journal of NuclearMedicine. Image courtesy of the Journal of NuclearMedicine.
An emerging PET/CT radiotracer may be more predictive of progressive pulmonary fibrosis in interstitial lung patients than F-18 FDG PET/CT, according to research presented June 8 at the 2024 Society of NuclearMedicine and Molecular Imaging Annual Meeting (SNMMI). Comparative analysis involved PET/CT parameters of both tracers.
PET/CT is poised to become a key tool for imaging the coronary arteries – a clinical imaging exam that can reveal early warning signs of fatal conditions when patients present with symptoms of chest pain, experts say. Coronary artery disease (CAD) is the leading cause of mortality in the U.S.
PET/CT imaging with a new gallium-68-based prostate cancer radiotracer shows promise for detecting recurrent metastatic disease, according to a study published February 20 in the Journal of NuclearMedicine. The finding is from a phase I/II clinical trial in the U.S. HU = Houndsfield unit; SUVbw = body-weight SUV.
PET/MRI scans have revealed immune system reactions after COVID-19 vaccines in children with cancer, according to a study published October 26 in the Journal of NuclearMedicine. Several studies have demonstrated that vaccine-related lymphadenopathy may confound disease assessment in oncology patients, the researchers added.
A recently developed PET radiotracer identified sources of pain in patients with complex regional pain syndrome (CRPS) and led to effective treatments, according to a study presented June 10 at the Society of NuclearMedicine and Molecular Imaging (SNMMI) annual meeting.
Alpha-emitting astatine-211 (At-211) may open the door to new targeted radioimmunotherapy for treating blood cancer, according to research presented June 10 at the Society of NuclearMedicine and Molecular Imaging (SNMMI) in Toronto. The studies support further clinical investigation.
Both FUO and IUO can be caused by a wide range of pathological processes, from malignancies, infections, and granulomatous and inflammatory diseases, to miscellaneous causes. Image courtesy of the European Journal of Radiology. In 33 (31.7%) patients, the etiology of IUO/FUO remained unknown.
more than 6 million Americans have Alzheimer's disease, a debilitating and far-reaching disease that accounts for 60% to 80% of dementia cases, and by 2050, this number is projected to rise to nearly 13 million, according to Alzheimer’s Disease International. The disease affects memory, thinking, and behavior. In the U.S.,
F-18 florbetaben PET scans for diagnosing Alzheimer’s disease can be reduced from 20 minutes to five minutes without losing accuracy, according to a recent study. Our findings suggest that shorter scan times are a viable and effective option for brain amyloid PET imaging in clinical settings,” the group wrote.
and European nuclearmedicine organizations have released joint guidelines on the use of fibroblast activation protein (FAP)-PET imaging in cancer patients. The guidelines were published in the January issue of the Journal of NuclearMedicine.
cleared deep learning algorithm that provides quantitative total disease burden on F-18 DCFPyL (Pylarify) PET/CT images. Recent clinical studies have shown that total quantitative burden with aPromise supports patient selection for prostate cancer radioligand therapy and automates monitoring response over time, Lantheus said.
Based on a novel clustering framework using sparse canonical correlation analysis (SCCA), the integrated approach was successful in identifying four subtypes of Alzheimer’s disease and the top genes associated with each, according to the authors of the study, “An SCCA-clustering framework for Alzheimer’s disease subtyping using tau PET and genomics.”
To address this knowledge gap, the authors pooled data from 281 patients with head and neck squamous cell carcinoma from two clinical trials conducted between 2004 and 2021. Among cases with hypoxia-negative disease before CRT, no patients experienced distant metastases. among those without it. among those without it.
Ultrasound model predicts liver disease progression. Assessment of Claimant, Clinical, and Financial Characteristics of Teleradiology Medical Malpractice Cases. Bodien, et al, New England Journal of Medicine , August 14, 2024. SPECT/CT reveals heart’s response to tafamidis. Francisco, et al, Emergency Radiology , April 26, 2024.
Nuclearmedicine is a form of specialty medicine that uses radioactive tracers to evaluate bodily functions and to diagnose and treat a wide range of health conditions. Nuclear scans produce images of the body’s anatomy that cannot be obtained as clearly or fully with other imaging techniques.
30, 2025 Earlier this month, the Society of NuclearMedicine and Molecular Imaging (SNMMI) and the Alzheimers Association released updated appropriate use criteria (AUC) for amyloid and tau PET imaging in patients with mild cognitive impairment, Alzheimers disease and other dementias. tim.hodson Thu, 01/30/2025 - 10:20 Jan.30,
christine.book Mon, 06/26/2023 - 12:46 June 26, 2023 — PET imaging with 68Ga-FAPI offers a feasible, reliable, and reproducible method for evaluating disease activity in rheumatoid arthritis, according to new research presented at the 2023 Society of NuclearMedicine and Molecular Imaging Annual Meeting.
In particular, the facility lacks a modern PACS and clinical decision-support tools. The attack affected critical departments, including the radiology department, which encompasses the Diagnostic Imaging department, Radiation Therapy Department, NuclearMedicine Department, Radiation safety, and Ultrasound diagnostics.
milla1cf Tue, 06/11/2024 - 18:41 June 11, 2024 — A newly developed radiotracer can generate high quality and readily interpretable images of cardiac amyloidosis, a condition referred to as the “Alzheimer’s disease of the heart.” This research was presented at the 2024 Society of NuclearMedicine and Molecular Imaging Annual Meeting.
announced that it has entered into a patent license agreement with Mayo Clinic for the rights to the PSMA Alpha-PET DoubLET platform technology for the treatment of PSMA-expressing cancers, with an initial focus on prostate. milla1cf Fri, 01/05/2024 - 11:21 January 5, 2024 — Perspective Therapeutics, Inc.
CPIC promotes federal policies that advance health outcomes for patients with cardiovascular disease. The coalition's founding members include CDL Nuclear Technologies, Bracco Diagnostics , and Siemens Healthineers.
Furthermore, fatigue has previously been linked to cognitive impairment in patients with Parkinson’s disease via a similar brain network as that involved in long COVID, they wrote. Potential therapeutic options could include ways to target the hypometabolism pattern revealed by the brain PET scans, the researchers wrote.
milla1cf Thu, 06/29/2023 - 21:10 June 29, 2023 — Blue Earth Therapeutics , a Bracco company and emerging leader in the development of innovative next generation therapeutic radiopharmaceuticals, today announced highlights from early clinical and preclinical studies of 177Lu-rhPSMA-10.1 177Lu-rhPSMA-10.1 177Lu-rhPSMA-10.1 177Lu-rhPSMA-10.1
Mahmood was presented the award by the Society of NuclearMedicine and Molecular Imaging (SNMMI) at its 2023 Annual Meeting. Award recipients will have initiated, developed, and successfully implemented unique and significant transformative value within the field of nuclearmedicine and molecular imaging.
milla1cf Tue, 08/15/2023 - 16:28 August 15, 2023 — In elderly patients with suspected prostate cancer, PSMA PET/CT can diagnose advanced disease and aid in therapy selection without the need for a biopsy. Compared with patients who did have a pre-imaging biopsy, these patients were older with worse clinical status and had higher PSA levels.
We organize all of the trending information in your field so you don't have to. Join 5,000 users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content